Table 4 Latent class analysis
Attribute levels | Class 1 estimate (SE) | P value | CI | RI | Class 2 estimate (SE) | P value | CI | RI |
|---|---|---|---|---|---|---|---|---|
Increase in physical functional capacity | 0.50 | 1 | ||||||
25% improvement (refa) | ||||||||
50% improvement | 1.0 (0.68) | N/Ab | -0.33 – 2.32 | 1.98 (0.48) | < 0.01 | 1.04 – 2.92 | ||
75% improvement | 2.08 (0.70) | < 0.01 | 0.71 – 4.45 | 2.95 (0.52) | < 0.01 | 1.93 – 3.97 | ||
100% improvement | 2.36 (0.81) | < 0.01 | 0.76 – 3.94 | 3.81 (0.60) | < 0.01 | 2.62 – 4.98 | ||
Increase in psychosocial functional capacity | 0.10 | 0.36 | ||||||
25% improvement (ref) | ||||||||
50% improvement | 0.11 (0.42) | N/A | -0.71 – 0.94 | 0.68 (0.25) | < 0.01 | 0.19 – 1.16 | ||
75% improvement | -0.12 (0.41) | N/A | -0.92 – 0.67 | 1.12 (0.29) | < 0.01 | 0.56 – 1.68 | ||
100% improvement | 0.45 (0.44) | N/A | -0.41 – 1.30 | 1.36 (0.27) | < 0.01 | 0.82 – 1.89 | ||
Frequency of mild side effects | 0.13 | 0.34 | ||||||
Low (ref) | ||||||||
Medium | -0.13 (0.28 | N/A | -0.68 – 0.40 | -0.46 (0.16) | < 0.01 | -0–77 – (-0.14) | ||
High | -0.61 (0.31) | < 0.05 | -1.21 – (-0.00) | -1.29 (0.21) | < 0.01 | -1.69 – (-0.88) | ||
Likelihood of severe side effects | 1 | 0.31 | ||||||
Rare: 1 in 1,000 (ref) | ||||||||
Common: 1 in 100 | -0.94 (0.42) | < 0.05 | -1.76 – (-0.11) | -0.38 (0.23) | N/A | -0.83 – 0.07 | ||
Very common: 1 in 10 | -4.69 (1.09) | < 0.01 | -6.82 – (-2.56) | -1.17 (0.31) | < 0.01 | -1.77 – (-0.07) | ||
Average class probability | 43 | 57 | ||||||